Business Description
Incyte Corp
NAICS : 541714
SIC : 8731
ISIN : US45337C1027
Share Class Description:
INCY: Ordinary SharesTotal Employee Number:
2,844Compare
Compare
Traded in other countries / regions
INCY.USA0J9P.UKI1NC34.BrazilICY.GermanyINCY.Mexico1INCY.ItalyINCY.Austria Index Membership
S&P 500Russell 1000Russell 3000MSCI World IndexNASDAQ 100 IPO Date
1993-11-03Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 101.85 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 620.56 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 10.43 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.1 | |||||
3-Year EBITDA Growth Rate | 48.5 | |||||
3-Year EPS without NRI Growth Rate | 34.7 | |||||
3-Year FCF Growth Rate | 18.5 | |||||
3-Year Book Growth Rate | 9.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.05 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.14 | |||||
9-Day RSI | 64.33 | |||||
14-Day RSI | 64.03 | |||||
3-1 Month Momentum % | 1.2 | |||||
6-1 Month Momentum % | -6.8 | |||||
12-1 Month Momentum % | 43.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.68 | |||||
Quick Ratio | 3.6 | |||||
Cash Ratio | 2.7 | |||||
Days Inventory | 80.99 | |||||
Days Sales Outstanding | 63.15 | |||||
Days Payable | 189.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.8 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.48 | |||||
Operating Margin % | 27.05 | |||||
Net Margin % | 26.71 | |||||
EBITDA Margin % | 34.9 | |||||
FCF Margin % | 26.5 | |||||
OCF Margin % | 28.29 | |||||
ROE % | 30.75 | |||||
ROA % | 22.23 | |||||
ROIC % | 39.88 | |||||
3-Year ROIIC % | 87.46 | |||||
ROC (Joel Greenblatt) % | 223.45 | |||||
ROCE % | 35.73 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.56 | |||||
Forward PE Ratio | 15.01 | |||||
PE Ratio without NRI | 15.76 | |||||
Shiller PE Ratio | 65.5 | |||||
Price-to-Owner-Earnings | 21 | |||||
PS Ratio | 4.44 | |||||
PB Ratio | 4.17 | |||||
Price-to-Tangible-Book | 4.36 | |||||
Price-to-Free-Cash-Flow | 16.84 | |||||
Price-to-Operating-Cash-Flow | 15.74 | |||||
EV-to-EBIT | 10.95 | |||||
EV-to-Forward-EBIT | 11.98 | |||||
EV-to-EBITDA | 10.39 | |||||
EV-to-Forward-EBITDA | 11.25 | |||||
EV-to-Revenue | 3.63 | |||||
EV-to-Forward-Revenue | 3.45 | |||||
EV-to-FCF | 13.69 | |||||
Price-to-GF-Value | 1.17 | |||||
Price-to-Projected-FCF | 1.98 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.82 | |||||
Price-to-Graham-Number | 1.75 | |||||
| Price-to-Net-Current-Asset-Value | 6.22 | |||||
| Price-to-Net-Cash | 10.2 | |||||
Earnings Yield (Greenblatt) % | 9.13 | |||||
FCF Yield % | 6.07 | |||||
Forward Rate of Return (Yacktman) % | 22.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Incyte Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5,361.02 | ||
| EPS (TTM) ($) | 7.08 | ||
| Beta | 0.8241 | ||
| 3-Year Sharpe Ratio | 0.72 | ||
| 3-Year Sortino Ratio | 1.2 | ||
| Volatility % | 26.4 | ||
| 14-Day RSI | 64.03 | ||
| 14-Day ATR ($) | 3.552545 | ||
| 20-Day SMA ($) | 112.9495 | ||
| 12-1 Month Momentum % | 43.59 | ||
| 52-Week Range ($) | 67.17 - 119.6 | ||
| Shares Outstanding (Mil) | 199.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Incyte Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Incyte Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 08:00 | In 103 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 07:00 | In 103 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 08:00 | In 11 days | ||
| Second quarter earnings results for 2026 | 2026-07-28 07:00 | In 11 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:40 | 100.64 (-2.07%) | ||
| General meeting for 2026 | 2026-06-08 10:00 | 102.38 (+1.18%) | ||
| Incyte Conference Call and Webcast | 2026-06-08 08:00 | 102.38 (+1.18%) | ||
| Guidance call for 2026 | 2026-05-19 10:30 | 95.19 (-0.30%) | ||
| Guidance call for 2026 | 2026-05-13 13:40 | 99.13 (-1.70%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 08:00 | 95.72 (+1.29%) |
Show
Entries
Incyte Corp Frequently Asked Questions
What is Incyte Corp(INCY)'s stock price today?
The current price of INCY is $117.27. The 52 week high of INCY is $119.60 and 52 week low is $67.17.
When is next earnings date of Incyte Corp(INCY)?
The next earnings date of Incyte Corp(INCY) is 2026-07-28.
Does Incyte Corp(INCY) pay dividends? If so, how much?
Incyte Corp(INCY) does not pay dividend.
Guru Commentaries on NAS:INCY
No articles.
Press Release
Articles on Incyte Corp
Headlines
See More- 1
Jul 02, 2026
Top Quant-rated momentum stocks as July is the most negative month for the momentum factor
Seeking Alpha • 10:53am
Jun 28, 2026
Notable healthcare headlines for the week: Merck, AbbVie, and Bayer in focus
Seeking Alpha • 8:05am
Jun 26, 2026
Acadia rises as EU backs Rett syndrome therapy
Seeking Alpha • 10:22am
Lilly, Incyte, CSL among winners of EU drug recommendations this week
Seeking Alpha • 9:29am
US stock futures mixed as mega-cap tech drags market sentiment
Seeking Alpha • 3:30am
Jun 21, 2026
Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus
Seeking Alpha • 8:05am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers